MarketWatch.com - Top Stories

This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments.

May 14, 2025 - 17:50
 0
This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent
Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments.
Read More

Tags:

Previous Article

Why are Republican senators fighting against federal budget cuts? Because they h...

Next Article

I’m 90, and the RMDs and taxes on my $1.5 million are huge. Is it too late for R...

Related Posts

AMC is taking this bold move to capitalize on a booming box office

AMC is taking this bold move to capitalize on a booming...

May 13, 2025  0

30 AI stocks that could surge up to 73% — and are loved by a bullish tech analyst

30 AI stocks that could surge up to 73% — and are loved...

May 10, 2025  0

Multimillionaires might face higher taxes under Trump. Here are the money moves they could make now to trim their tax bill.

Multimillionaires might face higher taxes under Trump. ...

May 10, 2025  0